Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...

Candel Therapeutics Inc. stock ended Wednesday deep in the red but rose 1.3% in extended trading after the company announced ...

The 10-week course at Stanford last fall was fully enrolled and packed with students eager to learn from Dr. Lin's unique ...

Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...

Treatment with CAN-2409, an off-the-shelf immunotherapy, elicited responses among patients with pretreated stage 3/4 ...

"Lung cancer ranks third in terms of new cases but second in terms of mortality in Vietnam. Of the over 24,000 new cases ...

Cancer remains a leading cause of death globally, with lung cancer being particularly lethal. Despite advancements in diagnostics and therapies, the five-year survival rates for advanced tumors have ...

Janssen-Cilag International NV has announced results from the phase 3 MARIPOSA study, demonstrating a significant overall ...

Get Instant Summarized Text (Gist) Increased use of chest X-rays in general practice is linked to earlier diagnosis and improved survival rates for lung cancer patients. Analysis of over 170,000 ...

Candel Therapeutics' CAN-2409 showed marginal survival benefit in lung cancer trial, with better results in non-squamous ...

The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...